Trade C4 Therapeutics, Inc. - CCCC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.12 |
| Open | 2.01 |
| 1-Year Change | -81.68% |
| Day's Range | 1.92 - 2.08 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 11, 2025 | 2.02 | -0.10 | -4.72% | 2.12 | 2.12 | 1.92 |
| Mar 10, 2025 | 2.12 | -0.14 | -6.19% | 2.26 | 2.29 | 2.08 |
| Mar 7, 2025 | 2.33 | 0.02 | 0.87% | 2.31 | 2.42 | 2.27 |
| Mar 6, 2025 | 2.31 | -0.01 | -0.43% | 2.32 | 2.36 | 2.25 |
| Mar 5, 2025 | 2.39 | 0.01 | 0.42% | 2.38 | 2.42 | 2.31 |
| Mar 4, 2025 | 2.34 | 0.06 | 2.63% | 2.28 | 2.36 | 2.18 |
| Mar 3, 2025 | 2.36 | -0.21 | -8.17% | 2.57 | 2.62 | 2.36 |
| Feb 28, 2025 | 2.67 | 0.13 | 5.12% | 2.54 | 2.70 | 2.44 |
| Feb 27, 2025 | 2.56 | -0.03 | -1.16% | 2.59 | 2.77 | 2.56 |
| Feb 26, 2025 | 2.61 | -0.12 | -4.40% | 2.73 | 2.78 | 2.59 |
| Feb 25, 2025 | 2.75 | -0.11 | -3.85% | 2.86 | 2.86 | 2.66 |
| Feb 24, 2025 | 2.85 | -0.17 | -5.63% | 3.02 | 3.04 | 2.82 |
| Feb 21, 2025 | 2.98 | 0.06 | 2.05% | 2.92 | 3.02 | 2.88 |
| Feb 20, 2025 | 2.95 | -0.01 | -0.34% | 2.96 | 2.97 | 2.76 |
| Feb 19, 2025 | 2.97 | 0.03 | 1.02% | 2.94 | 3.06 | 2.85 |
| Feb 18, 2025 | 2.94 | -0.18 | -5.77% | 3.12 | 3.20 | 2.94 |
| Feb 14, 2025 | 3.14 | 0.00 | 0.00% | 3.14 | 3.32 | 3.12 |
| Feb 13, 2025 | 3.16 | -0.15 | -4.53% | 3.31 | 3.35 | 3.16 |
| Feb 12, 2025 | 3.27 | 0.09 | 2.83% | 3.18 | 3.28 | 3.13 |
| Feb 11, 2025 | 3.23 | -0.05 | -1.52% | 3.28 | 3.30 | 3.17 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
C4 Therapeutics, Inc. Company profile
About C4 Therapeutics Inc
C4 Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on harnessing the body’s natural regulation of protein levels to develop therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions and other diseases. The Company provides technology platform, Target ORiented ProtEin Degrader Optimizer (TORPEDO), to synthesize a new class of small molecule protein degraders that are designed to destroy disease-causing proteins, including targets previously considered to be undruggable. The Company’s lead product candidates, CFT7455, is an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma (MM), peripheral T-cell lymphoma (PTCL), and mantle cell lymphoma (MCL). The Company is also developing CFT8634, an orally bioavailable degrader of a protein target called bromodomain containing 9 (BRD9), for synovial sarcoma and SMARCB1-deleted solid tumors.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, C4 Therapeutics Inc revenues increased 38% to $45.8M. Net loss increased 26% to $83.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Stock-based Compensation in SGA increase from $2.5M to $14M (expense), Research and development - Balancing val increase of 12% to $87.1M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
490 Arsenal Way
Suite 120
WATERTOWN
MASSACHUSETTS 02472
US
News
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com